Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 13, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-07-27
DOI
10.1186/s13045-020-00924-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hi-JAK-ing the ubiquitin system: The design and physicochemical optimisation of JAK PROTACs
- (2020) Rishi R. Shah et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and independent effects by CDK6-specific PROTACs
- (2020) Marco De Dominici et al. BLOOD
- Proteolysis‐targeting chimeras in drug development: A safety perspective
- (2020) Kevin Moreau et al. BRITISH JOURNAL OF PHARMACOLOGY
- Pharmacokinetics/Pharmacodynamic (PK/PD) relationship of therapeutic monoclonal antibodies used in oncology: what's new?
- (2020) Olivier Mir et al. EUROPEAN JOURNAL OF CANCER
- Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance
- (2020) Ning Sun et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions
- (2020) Ahmad I. Antar et al. LEUKEMIA
- Small-molecule targeted recruitment of a nuclease to cleave an oncogenic RNA in a mouse model of metastatic cancer
- (2020) Matthew G. Costales et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PROTACs: A novel strategy for cancer therapy
- (2020) Jing Liu et al. SEMINARS IN CANCER BIOLOGY
- Light-induced control of protein destruction by opto-PROTAC
- (2020) Jing Liu et al. Science Advances
- PHOTACs enable optical control of protein degradation
- (2020) Martin Reynders et al. Science Advances
- Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4
- (2020) Marı́a Maneiro et al. ACS Chemical Biology
- Mechanistic basis and efficacy of targeting the β-catenin–TCF7L2–JMJD6–c-Myc axis to overcome resistance to BET inhibitors
- (2020) Dyana T. Saenz et al. BLOOD
- Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity
- (2020) Xuan Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Azo-PROTAC: Novel Light-Controlled Small-Molecule Tool for Protein Knockdown
- (2020) Yu-Hui Jin et al. JOURNAL OF MEDICINAL CHEMISTRY
- How We Think about Targeting RNA with Small Molecules
- (2020) Matthew G. Costales et al. JOURNAL OF MEDICINAL CHEMISTRY
- Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs
- (2020) Ronen Gabizon et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Construction of a human cell landscape at single-cell level
- (2020) Xiaoping Han et al. NATURE
- PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
- (2020) Sajid Khan et al. ONCOGENE
- Development of Selective Histone Deacetylase 6 (HDAC6) Degraders Recruiting Von Hippel–Lindau (VHL) E3 Ubiquitin Ligase
- (2020) Ka Yang et al. ACS Medicinal Chemistry Letters
- Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity
- (2020) Yonghan He et al. Nature Communications
- Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines
- (2020) Xuan Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- A novel cereblon modulator for targeted protein degradation
- (2019) Sung Ah Kim et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
- (2019) Rumani Singh et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Developing potent PROTACs tools for selective degradation of HDAC6 protein
- (2019) Zixuan An et al. Protein & Cell
- Recent advances in the development of Mcl-1 inhibitors for cancer therapy
- (2019) Alexander W. Hird et al. PHARMACOLOGY & THERAPEUTICS
- Degradation of Bruton’s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas
- (2019) Yonghui Sun et al. LEUKEMIA
- Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications
- (2019) Carl C. Ward et al. ACS Chemical Biology
- RUNX1 targeted therapy for AML expressing somatic or germline mutation in RUNX1
- (2019) Christopher P Mill et al. BLOOD
- BETP degradation simultaneously targets acute myelogenous leukemic stem cells and the microenvironment
- (2019) Sujan Piya et al. JOURNAL OF CLINICAL INVESTIGATION
- From Inhibition to Degradation: Targeting the Anti-apoptotic Protein Myeloid Cell Leukemia 1 (MCL1)
- (2019) James William Papatzimas et al. JOURNAL OF MEDICINAL CHEMISTRY
- Acquired Resistance to BET-PROTACs(Proteolysis Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 ligase Complexes
- (2019) Lu Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Cyclin D-Cdk4,6 Drives Cell-Cycle Progression via the Retinoblastoma Protein’s C-Terminal Helix
- (2019) Benjamin R. Topacio et al. MOLECULAR CELL
- Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia
- (2019) Christine M. McMahon et al. Cancer Discovery
- Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated Targeted Protein Degradation
- (2019) George M Burslem et al. CANCER RESEARCH
- Comprehensive Integration of Single-Cell Data
- (2019) Tim Stuart et al. CELL
- Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity
- (2019) Hao Wu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Harnessing the anti-cancer natural product nimbolide for targeted protein degradation
- (2019) Jessica N. Spradlin et al. Nature Chemical Biology
- BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
- (2019) William Farnaby et al. Nature Chemical Biology
- Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16
- (2019) Xiaoyu Zhang et al. Nature Chemical Biology
- Disruption of IRE1α through its kinase domain attenuates multiple myeloma
- (2019) Jonathan M. Harnoss et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma
- (2019) Neeraj Jain et al. Science Translational Medicine
- Targeting IRAK4 for Degradation with PROTACs
- (2019) Joao Nunes et al. ACS Medicinal Chemistry Letters
- MCL-1 inhibitors – where are we now (2019)?
- (2019) Steven Fletcher EXPERT OPINION ON THERAPEUTIC PATENTS
- Development and Clinical Trials of Nucleic Acid Medicines for Pancreatic Cancer Treatment
- (2019) Keiko Yamakawa et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders
- (2019) Shang Su et al. JOURNAL OF MEDICINAL CHEMISTRY
- Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK)
- (2019) Xiaotian Kong et al. JOURNAL OF MEDICINAL CHEMISTRY
- Proteolysis Targeting Chimeras for the Selective Degradation of Mcl-1/Bcl-2 Derived from Nonselective Target Binding Ligands
- (2019) Ziqian Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs
- (2019) Patrick Pfaff et al. ACS Central Science
- Development of Small Molecule Chimeras That Recruit AhR E3 Ligase to Target Proteins
- (2019) Nobumichi Ohoka et al. ACS Chemical Biology
- Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells
- (2019) Xupeng Mu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
- (2019) Longchuan Bai et al. CANCER CELL
- Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity
- (2019) Thomas H. Pillow et al. ChemMedChem
- Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel–Lindau (VHL) E3 Ubiquitin Ligase
- (2019) Quanju Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Light-Induced Protein Degradation with Photocaged PROTACs
- (2019) Gang Xue et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Targeted protein degradation: expanding the toolbox
- (2019) Matthieu Schapira et al. NATURE REVIEWS DRUG DISCOVERY
- Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies
- (2019) Fei Jiang et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)
- (2019) Peter S. Dragovich et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties
- (2019) Saul Jaime-Figueroa et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein
- (2019) Haibin Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a first-in-class EZH2 selective degrader
- (2019) Anqi Ma et al. Nature Chemical Biology
- A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
- (2019) Sajid Khan et al. NATURE MEDICINE
- Discovery of an Irreversible and Cell-Active BCL6 Inhibitor Selectively Targeting Cys53 Located at the Protein–Protein Interaction Interface
- (2018) Tomoya Sameshima et al. BIOCHEMISTRY
- Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation
- (2018) Alexandru D. Buhimschi et al. BIOCHEMISTRY
- Development of the first small molecule histone deacetylase 6 (HDAC6) degraders
- (2018) Ka Yang et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
- (2018) Yonghui Sun et al. CELL RESEARCH
- Design and synthesis of novel bispecific molecules for inducing BRD4 protein degradation
- (2018) Shihui Wang et al. CHEMICAL RESEARCH IN CHINESE UNIVERSITIES
- Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)
- (2018) Chengwei Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- BCL6 as a therapeutic target for lymphoma
- (2018) Rebecca J Leeman-Neill et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation
- (2018) Nobumichi Ohoka et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)
- (2018) Chelsea E. Powell et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression
- (2018) Chong Qin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma
- (2018) Xiaohui Zhang et al. LEUKEMIA
- Plasticity in binding confers selectivity in ligand-induced protein degradation
- (2018) Radosław P. Nowak et al. Nature Chemical Biology
- Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands
- (2018) Lara N. Gechijian et al. Nature Chemical Biology
- Targeting the IL-6/JAK/STAT3 signalling axis in cancer
- (2018) Daniel E. Johnson et al. Nature Reviews Clinical Oncology
- Delineating the role of cooperativity in the design of potent PROTACs for BTK
- (2018) Adelajda Zorba et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Modulating PCAF/GCN5 Immune Cell Function through a PROTAC Approach
- (2018) Zuni I. Bassi et al. ACS Chemical Biology
- Homo-PROTACs for the Chemical Knockdown of Cereblon
- (2018) Christian Steinebach et al. ACS Chemical Biology
- The cutting-edge technologies of siRNA delivery and their application in clinical trials
- (2018) Kyuri Lee et al. ARCHIVES OF PHARMACAL RESEARCH
- Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)
- (2018) Chung Hyo Kang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- CRISPR-Cas9 - a new addition to the drug metabolism and disposition tool box
- (2018) Maria Karlgren et al. DRUG METABOLISM AND DISPOSITION
- ZFAND5/ZNF216 is an activator of the 26S proteasome that stimulates overall protein degradation
- (2018) Donghoon Lee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Emerging EZH2 Inhibitors and Their Application in Lymphoma
- (2018) Jennifer K. Lue et al. Current Hematologic Malignancy Reports
- Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome
- (2018) Katherine A Donovan et al. eLife
- Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6
- (2018) William McCoull et al. ACS Chemical Biology
- Bruton's Tyrosine Kinase degradation as a therapeutic strategy for cancer
- (2018) Dennis Dobrovolsky et al. BLOOD
- MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53
- (2018) John Hines et al. CANCER RESEARCH
- Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers
- (2018) Julien P. N. Papillon et al. JOURNAL OF MEDICINAL CHEMISTRY
- Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel–Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7
- (2018) Vittoria Zoppi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression
- (2018) Yangbing Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Enhancing Antiproliferative Activity and Selectivity of a FLT-3 Inhibitor by Proteolysis Targeting Chimera Conversion
- (2018) George M. Burslem et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
- (2018) Quinlan L. Sievers et al. SCIENCE
- Different Degradation Mechanisms of Inhibitor of Apoptosis Proteins (IAPs) by the Specific and Nongenetic IAP-Dependent Protein Eraser (SNIPER)
- (2018) Nobumichi Ohoka et al. CHEMICAL & PHARMACEUTICAL BULLETIN
- MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer
- (2017) Veronica Tisato et al. Journal of Hematology & Oncology
- Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands
- (2017) Norihito Shibata et al. JOURNAL OF MEDICINAL CHEMISTRY
- Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds
- (2017) Kwok-Ho Chan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?
- (2017) Ian Churcher JOURNAL OF MEDICINAL CHEMISTRY
- Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals)
- (2017) Matthias Schiedel et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression
- (2017) Bing Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells
- (2017) D T Saenz et al. LEUKEMIA
- BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells
- (2017) B Sun et al. LEUKEMIA
- BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment
- (2017) Georg E. Winter et al. MOLECULAR CELL
- An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED
- (2017) Wei Qi et al. Nature Chemical Biology
- Structural basis of PROTAC cooperative recognition for selective protein degradation
- (2017) Morgan S Gadd et al. Nature Chemical Biology
- HSP70-Hrd1 axis precludes the oncorepressor potential of N-terminal misfolded Blimp-1s in lymphoma cells
- (2017) Wen-Fang Wang et al. Nature Communications
- Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation
- (2017) Chiara Maniaci et al. Nature Communications
- Targeting ALK: Precision Medicine Takes on Drug Resistance
- (2017) Jessica J. Lin et al. Cancer Discovery
- Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6
- (2017) Nina Kerres et al. Cell Reports
- Complex heatmaps reveal patterns and correlations in multidimensional genomic data
- (2016) Zuguang Gu et al. BIOINFORMATICS
- Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand
- (2016) Yosuke Demizu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target
- (2016) Mariano G. Cardenas et al. CLINICAL CANCER RESEARCH
- The roles of Polycomb group proteins in hematopoietic stem cells and hematological malignancies
- (2016) Emi Takamatsu-Ichihara et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma
- (2016) Mariano G. Cardenas et al. JOURNAL OF CLINICAL INVESTIGATION
- Identification and Development of 2,3-Dihydropyrrolo[1,2-a]quinazolin-5(1H)-one Inhibitors Targeting Bromodomains within the Switch/Sucrose Nonfermenting Complex
- (2016) Charlotte L. Sutherell et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification of a Chemical Probe for Family VIII Bromodomains through Optimization of a Fragment Hit
- (2016) Brian S. Gerstenberger et al. JOURNAL OF MEDICINAL CHEMISTRY
- A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
- (2016) Mary E. Matyskiela et al. NATURE
- Induced protein degradation: an emerging drug discovery paradigm
- (2016) Ashton C. Lai et al. NATURE REVIEWS DRUG DISCOVERY
- Endoplasmic reticulum-resident E3 ubiquitin ligase Hrd1 controls B-cell immunity through degradation of the death receptor CD95/Fas
- (2016) Sinyi Kong et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
- (2016) Kanak Raina et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Sel1L-Hrd1 Endoplasmic Reticulum-Associated Degradation Complex Manages a Key Checkpoint in B Cell Development
- (2016) Yewei Ji et al. Cell Reports
- Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
- (2015) Michael Zengerle et al. ACS Chemical Biology
- Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL
- (2015) Ashton C. Lai et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants
- (2015) I. Chachoua et al. BLOOD
- Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis
- (2015) C. Marty et al. BLOOD
- The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
- (2015) Bhavatarini Vangamudi et al. CANCER RESEARCH
- Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
- (2015) Jing Lu et al. CHEMISTRY & BIOLOGY
- WSB1 promotes tumor metastasis by inducing pVHL degradation
- (2015) Jung Jin Kim et al. GENES & DEVELOPMENT
- Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice
- (2015) J Etchin et al. LEUKEMIA
- Negative Regulation of CARD11 Signaling and Lymphoma Cell Survival by the E3 Ubiquitin Ligase RNF181
- (2015) Sarah M. Pedersen et al. MOLECULAR AND CELLULAR BIOLOGY
- Catalytic in vivo protein knockdown by small-molecule PROTACs
- (2015) Daniel P Bondeson et al. Nature Chemical Biology
- HDAC inhibitors still need a home run, despite recent approval
- (2015) Malini Guha NATURE REVIEWS DRUG DISCOVERY
- CDK6—a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation
- (2015) A-S Tigan et al. ONCOGENE
- Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors
- (2015) V Gibaja et al. ONCOGENE
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- EZH2 in normal hematopoiesis and hematological malignancies
- (2015) Laurie Herviou et al. Oncotarget
- Requirement for CDK6 in MLL-rearranged acute myeloid leukemia
- (2014) T. Placke et al. BLOOD
- Presence of calreticulin mutations in JAK2-negative polycythemia vera
- (2014) J. Broseus et al. BLOOD
- Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: molecular mechanisms and therapeutic opportunities
- (2014) S Fulda LEUKEMIA
- The Neddylation-Cullin 2-RBX1 E3 Ligase Axis Targets Tumor Suppressor RhoB for Degradation in Liver Cancer
- (2014) Junfeng Xu et al. MOLECULAR & CELLULAR PROTEOMICS
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers
- (2014) G. R. Hoffman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Kinase-Independent Mechanisms of Resistance of Leukemia Stem Cells to Tyrosine Kinase Inhibitors
- (2014) Christine Victoria Ichim Stem Cells Translational Medicine
- The zinc-binding region (ZBR) fragment of Emi2 can inhibit APC/C by targeting its association with the coactivator Cdc20 and UBE2C-mediated ubiquitylation
- (2014) Shisako Shoji et al. FEBS Open Bio
- Expedient Synthesis of Highly Potent Antagonists of Inhibitor of Apoptosis Proteins (IAPs) with Unique Selectivity for ML-IAP
- (2013) Mitchell Vamos et al. ACS Chemical Biology
- Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)
- (2013) J. A. Woyach et al. BLOOD
- A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis
- (2013) Karoline Kollmann et al. CANCER CELL
- Development of hybrid small molecules that induce degradation of estrogen receptor-alpha and necrotic cell death in breast cancer cells
- (2013) Keiichiro Okuhira et al. CANCER SCIENCE
- Polycomb Repressive Complex 2 Regulates Normal Hematopoietic Stem Cell Function in a Developmental-Stage-Specific Manner
- (2013) Huafeng Xie et al. Cell Stem Cell
- Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation
- (2013) J. Shi et al. GENES & DEVELOPMENT
- FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance
- (2013) Michael R. Grunwald et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Antisense battles small molecule for slice of rare lipid disorder market
- (2013) Gunjan Sinha NATURE BIOTECHNOLOGY
- Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy
- (2013) Cigall Kadoch et al. NATURE GENETICS
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
- (2013) J. Nangalia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
- (2013) Thorsten Klampfl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- The API2–MALT1 fusion exploits TNFR pathway-associated RIP1 ubiquitination to promote oncogenic NF-κB signaling
- (2013) S Rosebeck et al. ONCOGENE
- Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs
- (2013) J. Hines et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Small-Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1α
- (2012) Dennis L. Buckley et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed
- (2012) Berkley E Gryder et al. Future Medicinal Chemistry
- A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia
- (2012) C. Simon et al. GENES & DEVELOPMENT
- EED mutants impair polycomb repressive complex 2 in myelodysplastic syndrome and related neoplasms
- (2012) T Ueda et al. LEUKEMIA
- The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
- (2012) Jinghui Zhang et al. NATURE
- Development of target protein-selective degradation inducer for protein knockdown
- (2011) Yukihiro Itoh et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
- (2011) A. Hamilton et al. BLOOD
- Polycomb proteins in hematologic malignancies
- (2010) D. Martin-Perez et al. BLOOD
- Opposing roles of polycomb repressive complexes in hematopoietic stem and progenitor cells
- (2010) I. J. Majewski et al. BLOOD
- Protein Knockdown Using Methyl Bestatin−Ligand Hybrid Molecules: Design and Synthesis of Inducers of Ubiquitination-Mediated Degradation of Cellular Retinoic Acid-Binding Proteins
- (2010) Yukihiro Itoh et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review
- (2010) Xin An et al. LEUKEMIA RESEARCH
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- Brd2disruption in mice causes severe obesity without Type 2 diabetes
- (2009) Fangnian Wang et al. BIOCHEMICAL JOURNAL
- Modes of p53 Regulation
- (2009) Jan-Philipp Kruse et al. CELL
- Double bromodomain-containing gene Brd2 is essential for embryonic development in mouse
- (2009) Enyuan Shang et al. DEVELOPMENTAL DYNAMICS
- Control of mitochondrial apoptosis by the Bcl-2 family
- (2009) J. K. Brunelle et al. JOURNAL OF CELL SCIENCE
- Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics
- (2008) Ashley R. Schneekloth et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Chromosomal translocations: revisited yet again
- (2008) J. D. Rowley BLOOD
- Roles of unphosphorylated STATs in signaling
- (2008) Jinbo Yang et al. CELL RESEARCH
- Lysine Acetylation: Codified Crosstalk with Other Posttranslational Modifications
- (2008) Xiang-Jiao Yang et al. MOLECULAR CELL
- Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
- (2008) Richard F. Schlenk et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chromosomal Abnormalities in Cancer
- (2008) Stefan Fröhling et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started